Filing Flows › Avalo Therapeutics (AVTX) › Q4 2025 › vs Q4 2024
Avalo Therapeutics (AVTX) Q4 2025 vs Q4 2024 (year over year)
Avalo Therapeutics's revenue fell $133K (-69%) from $192K in Q4 2024 to $59K in Q4 2025.
Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year), net loss $13.7M, operating cash flow −$14.2M. The chart draws each line against Q4 2024, the increases inside each band.
Every line
| Line | Q4 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $59K | $192K | −$133K | -69% |
| Other income, net | $6.2M | −$21.9M | $28.1M | — |
| Net loss | $13.7M | $35.3M | −$21.6M | -61% |
| Costs & expenses | $19.9M | $35.5M | −$15.6M | -44% |
| Operating costs | $19.8M | $13.5M | $6.3M | +47% |
| Income tax | $130K | $114K | $16K | +14% |
| Research & development | $13.3M | $8.2M | $5.1M | +62% |
| General & admin | $6.5M | $5.2M | $1.3M | +25% |
| Operating cash sources | $18.8M | $18.0M | $754K | +4% |
| Depreciation & amortization | $16K | $68K | −$52K | -76% |
| Share-based compensation | $4.5M | $2.9M | $1.6M | +55% |
| Cash used in operations | $14.2M | $15.0M | −$798K | -5% |
| Net loss absorbed | $13.7M | $35.3M | −$21.6M | -61% |
| Working capital & other | $5.0M | −$17.3M | $22.4M | — |
Questions
How much did Avalo Therapeutics's revenue grow year over year in Q4 2025?
Avalo Therapeutics's revenue fell $133K (-69%) from $192K in Q4 2024 to $59K in Q4 2025.